Schedule 13D ownership disclosure
Prelude Therapeutics, Inc.
Security class unavailable · CUSIP: 74065P101
Event date: 2023-05-18
Legacy cover-page extraction is best effort and may not include every reporting person.
- Filing-level shares
- 10,219,080
- Percent of class
- 19.5000%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001104659-23-064148
- Form type
- SC 13D
- Filer
- BAKER BROS. ADVISORS LP
- CIK
- CIK 1263508
- Filed
- May 24, 2023
- Reporting period
- May 18, 2023
- Description
- Schedule 13D beneficial ownership